

9 Literaturverzeichnis

Air Liquide. 2004. Personal Communication.

Akkar, A. 2004. Poorly soluble drugs: formulation by nanocrystals and SolEmuls technologies. Dissertation. Freie Universität Berlin.

Akkar, A. and Muller, R. H. 2003a. Formulation of intravenous Carbamazepine emulsions by SolEmuls technology. *Eur J Pharm Biopharm* 55:305-12.

Akkar, A. and Muller, R. H. 2003b. Intravenous itraconazole emulsions produced by SolEmuls technology. *Eur J Pharm Biopharm* 56:29-36.

Akkar, A., Namsolleck, P., Blaut, M. and Müller, R. H. 2004. Solubilizing Poorly Soluble Antimycotic Agents by Emulsification via a Solvent-Free Process. *AAPS Pharm Sci Tech* 5:article 24.

Alpharma. 2002. Analysenzertifikat Amphotericin B. Alpharma ApS, Kopenhagen.

Anaissie, E. J., White, M., Uzun, O., Singer, C., Bodey, G. P., N. Azarnia, M. D. and Lopez-Berenstein, G. 1995. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: A prospective, randomized, multicenter trial. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Proceedings: abstr LM 21.

Anderson, N. L. and Anderson, N. G. 1991. A two-dimensional gel database of human plasma proteins. *Electrophoresis* 12:833-906.

Arikan, S. and Rex, J. H. 2001. Lipid-based antifungal agents: current status. *Curr Pharm Des* 7:393-415.

AstraZeneca. 2003. Fachinformation Antra pro infusione. AstraZeneca GmbH, Wedel.

Bangham, A. D. 1968. Membrane models with phospholipids. *Prog Biophys Mol Biol* 18:29.

Barquist, E., Fein, E., Shadick, D., Johnson, J., Clark, J. and Shatz. 1999. A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients. *J Trauma* 47:336-40.

Barwicz, J. and Tancrede, P. 1997. The effect of aggregation state of amphotericin-B on its interactions with cholesterol- or ergosterol-containing phosphatidylcholine monolayers. *Chem Phys Lipids* 85:145-55.

Bauer, K. H., Frömming, K.-H. and Führer, C. 2002. Pharmazeutischen Technologie. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.

Baum, J. 1994. Niedrigflussnarkosen. *Anaesthesist* 43:194-210.

Baum, J. 1998. Niedrigflussnarkosen mit dem Narkosebeatmungsgerät Ventilog 2. *Anaesthesist* 47:361-364.

- Baxter. 2001. Fachinformation ClinOleic 20% Baxter Deutschland GmbH, Unterschleißheim.
- Baxter GmbH. 2002. Produktinformationen: ClinOleic 20% Fettemulsion mit Olivenöl für die parenterale Ernährung. J Ernährungsmed 4.
- Beck, T., Fricke, U., Gielen, W., Jähnchen, E., Klotz, U., Kroemer, H. K., Kullmann, R., Kuschinsky, K., Meyer, W., Müller, W. E., Peters, H.-D., Reimann, I., Ruoff, H.-J., Schmitz, W., Schulz, M., Siewert, M., Verspohl, E. J., Vogel, B. and Ziegler, A. 1982. Arzneistoff-Profile Basisinformation über arzneiliche Wirkstoffe 11. Erg.-Lieferung 1996. Govi-Verlag Pharmazeutischer Verlag GmbH, Frankfurt am Main/Eschborn.
- Beckmann Coulter. 2000. Nicht-sphärische Partikel analysieren. Labor Praxis 5:Sonderdruck.
- Behnke, A. R. and Yarborough, O. D. 1938. Physiologic studies of helium. US nav med Bull 36:542-548.
- Bekersky, I., Boswell, G. W., Hiles, R., Fielding, R. M., Buell, D. and Walsh, T. J. 1999. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm Res 16:1694-701.
- Bekersky, I., Fielding, R. M., Buell, D., Lawrence, I. 1999. Lipid-based amphotericin B formulations: from animals to man. PSTT 2:230-236.
- Belazsovits, J. A., Mayer, L. D., Bally, M. B., Cullis, P. R., McDonell, M., Ginsberg, R. S. and Falk, R. E. 1989. Analysis of the effect of liposomal encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23:81-86.
- Benita, S. and Levy, M. Y. 1993. Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterization. J Pharm Sci 82:1069-79.
- Bennett, J. E. 1995. Antimicrobial Agents: Antifungal Agents. Pages 1175-1190. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics (J. G. Hardmann and L. E. Limbird, Hrsg.). McGraw-Hill, New York.
- Bisgaier, C. L., Siebenkas, M. V. and Williams, K. J. 1989. Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes. J Biol Chem 264:862-866.
- Bjellquist, B., Pasquali, C., Ravier, F., Sandchez, J.-C. and Hochstrasser, D. F. 1993. A non-linear immobilized pH gradient for two-dimensional electrophoresis and its definition in a relevant pH scale. Electrophoresis 14:1357-1365.
- Block, E. R., Bennett, J. E., Livoti, L. G., Klein, W. J., Jr., MacGregor, R. R. and Henderson, L. 1974. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. Ann Intern Med 80:613-7.
- Blunk, T. 1994. Plasmaproteinadsorption auf kolloidalen Arzneistoffträgern. Dissertation. Christian-Albrechts-Universität zu Kiel.

- Boberg, J. 1964. Physical and Biological Changes in an Artificial Fat Emulsion During Storage. *J Pharm Pharmacol* 16:641-6.
- Bock, T. K. 1994. Emulsionen als parenterale Arzneistoffträgersysteme - Herstellung, Charakterisierung and Optimierung. Dissertation. Christian-Albrechts-Universität zu Kiel.
- Bock, T. K., Lucks, J.-S., Kleinebudde, P., Müller, R. H. and Müller, B. W. 1994. High pressure homogenisation of parenteral fat emulsions - influence of process parameters on emulsion quality. *Eur J Pharm Biopharm* 40:157-160.
- Bodey, G., Bueltmann, B., Duguid, W., Gibbs, D., Hanak, H., Hotchi, M., Mall, G., Martino, P., Meunier, F., Milliken, S. and et al. 1992. Fungal infections in cancer patients: an international autopsy survey. *Eur J Clin Microbiol Infect Dis* 11:99-109.
- Bolard, J. 1986. How do the polyene macrolide antibiotic affect the cellular membrane properties. *Biochim Biophys Acta* 864:297-304.
- Boomsma, F., Ruprecht, J., Man in'tVeld, A. J., de Jong, F. H., Dzoljic, M. and Lachmann, B. 1990. Haemodynamic and neurohumoral effects of xenon anaesthesia. A comparison with nitrous oxide. *Anaesthesia* 45:273-278.
- Boothe, D. M. 2001. Drugs Affecting Gastrointestinal Function. Pages 1041-1063. In: *Veterinary Pharmacology and Therapeutics* (H. R. Adams, ed.) Iowa State University Press, Ames, USA.
- Bristol-Myers-Squibb. 2001. Gebrauchsinformation Amphotericin B Bristol-Myers Squibb GmbH, München.
- Brunner, U. 1999. Edelgas intravenös verbessert die Anästhesie. *PZ* 32.
- Buchmann, S., Fischli, W., Thiel, F. P., Alex, R. 1996. Aqueous microsuspension, an alternative intravenous formulation for animal studies. In: 42nd Annual Congress of the International Association for Pharmaceutical Technology (APV), Mainz:124.
- Burnham, W. R., Hansrani, P. K., Knott, C. E., Cook, J. A. and Davis, S. S. 1983. Stability of a fat emulsion based intravenous feeding mixture. *Int J Pharm* 13:9-22.
- Bushrab, F. N. 2005. Dissertation in preparation. Freie Universität Berlin.
- Caillot, D., Reny, G., Solary, E., Casasnovas, O., Chavanet, P., Bonnotte, B., Perello, L., Dumas, M., Entezam, F. and Guy, H. 1994. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. *J Antimicrob Chemother* 33:603-13.
- Calzia, E., Stahl, W., GHandschuh, T., Marx, T., Froeba, G., Bader, S., Georgieff, M. and Radermacher, P. 1999. Respiratory Mechanics during Xenon Anesthesia in Pigs: Comparison with Nitrous Oxide. *Anesthesiology* 91:1378-86.
- Carpentier, Y. A., Richelle, M., Bihain, B. E., Dahlan, W., Haumont, D. and Deckelbaum, R. J. 1987. Interactions between exogenous fat and plasma/lipoproteins. *Infusionsther Klin Ernähr* 14 Suppl 3:29-32.

- Carreno-Gomez, B., Woodley, J. F. and Florence, A. T. 1999. Studies on the uptake of tomato lectin nanoparticles in everted gut sacs. *International Journal of Pharmaceutics*. 183:7-11.
- Castro, D., Moreno, M. A., Torrado, S. and Lastres, J. L. 1999. Comparison of derivative spectrophotometric and liquid chromatographic methods for the determination of omeprazole in aqueous solutions during stability studies. *J Pharm Biomed Anal* 21:291-8.
- Chavanet, P., Duong, M., Buisson, M., Hamel, H., Dubois, C., Bonnin, A. and Portier, H. 1997. In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits. *J Antimicrob Chemother* 39:427-30.
- Chavanet, P. Y., Garry, I., Charlier, N., Caillot, D., Kisterman, J. P., D'Athis, M. and Portier, H. 1992. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. *Bmj* 305:921-5.
- CIBA-Geigy. 1975. *Documenta Geigy, Wissenschaftliche Tabellen*. Ciba-Geigy Ltd., Basel.
- Cohen, B. E. 1998. Amphotericin B toxicity and lethality: a tale of two channels. *Int J Pharm* 162:95-106.
- Collins-Gold, L. C., Lyons, R. T. and Bartholow, L. C. 1990. Parenteral emulsions for drug delivery. *Adv. Drug Deliv. Rev.* 5:189-208.
- Costa, S. and Nucci, M. 2001. Can we decrease amphotericin nephrotoxicity. *Curr Op Crit Care* 7:379-383.
- Craig, D. 1995. *Dielectric analysis of pharmaceutical systems*. Taylor & Francis.
- CRC Handbook of Chemistry and Physics. 1977-78. 58th edition. CRS press.
- Cullen, S. C. and Gross, E. G. 1951. The anaesthetic properties of xenon in animals and human beings with additional observations on krypton. *Science* 133:580-582.
- Davis, S. S. 1974. Pharmaceutical aspects of intravenous fat emulsions. *J Hosp Pharm Supplement*:149-160, 165-170.
- Davis, S. S. 1982. The stability of fat emulsions for intravenous administration. Pages 213-239. In: *Advances in clinical nutrition* (I. D. A. Johnston, ed.) MTP Press limited, Lancaster, UK.
- Davis, S. S., Illum, L., Muller, R., Landry, F., Wright, J. and Harper, G. 1990. The effect of infused fat emulsions on the reticuloendothelial function in the rabbit. *Clin Nutr* 9:260-265.
- Davis, S. S. and Washington, C. 1988. Drug emulsion. European Patent 0296845A1.
- Davis, S. S. and Washington, C. 1995. Preparation of oil-in-water emulsions of drugs. US Patent 5,389,373.

- Davis, S. S., Washington, C., West, P., Illum, L., Liversidge, G., Sternson, L. and Kirsh, R. 1987. Lipid emulsions as drug delivery systems. *Ann N Y Acad Sci* 507:75-88.
- Deutsche Gesellschaft für Hygiene and Mikrobiologie. 1991. Richtlinie für die Prüfung and Bewertung chemischer Desinfektionsverfahren. Pages erster Teilabschnitt. In: DGHM-Richtlinie 1991 (J. M. Bornitt, ed.) mhp, Wiesbaden.
- Dingley, J. and Hughes, L. G. 2000. Xenon: a replacement for nitrous oxide. *Current Opinion in Anaesthesiology* 13:443-447.
- Dirks, S., Vorwalter, C., Grünert, A. and Ahnefeld, F. W. 1988. Basal plasma-catecholamine-level determination using HPLC-ED and different sample cleanup techniques. *Chromatographia* 25:223-229.
- Driscoll, D. F., Bhargava, H. N., Li, L., Zaim, R. H., Babayan, V. K. and Bistran, B. R. 1995. Physicochemical stability of total nutrient admixtures. *Am J Health Syst Pharm* 52:623-34.
- Driscoll, D. F., Giampietro, K., Wichelhaus, D. P., Peterss, H., Nehne, J., Niemann, W. and Bistran, B. R. 2001. Physicochemical stability assessments of lipid emulsions of varying oil composition. *Clin Nutr* 20:151-7.
- Duro, R., Gómez-Amosa, J. L., Martínez-Pacheco, R., Souto, C. and Concheiro, A. 1998. Adsorption of polysorbate 80 on pyrantel pamoate: effects on suspension stability. *Int J Pharm* 165:211-216.
- Dutta, S. and Ebling, W. F. 1997. Emulsion formulation reduces propofol's dose requirements and enhances safety. *Anesthesiology* 87:1394-405.
- Eckart, J., Adolph, M., van der Muhlen, U. and Naab, V. 1980. Fat emulsions containing medium chain triglycerides in parenteral nutrition of intensive care patients. *Jpn: Journal of Parenteral & Enteral Nutrition*. 4:360-6.
- Eger, E. I., Johnson, B. H., Weiskopf, R. B., Holmes, M. A., Yasuda, N., Targ, A. and Rampil, I. J. 1988. Minimum alveolar concentration of I-653 and isoflurane in pigs: definition of a supramaximal stimulus. *Anesth Analg* 67:1174-1176.
- Eger, R. P. and MacLeod, B. A. 1995. Anaesthesia by intravenous emulsified isoflurane in mice. *Can J Anaesth* 42:173-176.
- Egito, E. S. T., Araújo, I.B., Damasceno, B.P.G.L., Price, J.C. 2002. Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B toxicity. *JPharmSci* 91:2354-2366.
- Egito, E. S. T., Fessi, H., Appel, M., Barrat, G., Legrand, P., Bolard, J. and Devissaguet, J.-P. 1996. A morphological study of an amphotericin B emulsion-based delivery system. *Int J Pharm* 145:17-27.
- Ekpe, A. and Jacobsen, T. 1999. Effect of various salts on the stability of lansoprazole, omeprazole, and pantoprazole as determined by high-performance liquid chromatography. *Drug Dev Ind Pharm* 25:1057-65.

- Ericsson, O., Hallmen, A. and Wikstrom, I. 1996. Amphotericin B is incompatible with lipid emulsions. *Ann Pharmacother* 30:298.
- Fiedler, H. P. 1996. *Lexikon der Hilfsstoffe für Pharmazie, Kosmetik and angrenzende Gebiete*, 4.Auflage. Editio Cantor Verlag Aulenhof.
- Florence, A. T. and Attwood, D. 1981. *Physico chemical principles of pharmacy*. Chapman and Hall, New York.
- Forth, W., Henschler, D., Rummel, W. and Starke, K. 1996. *Allgemeine and spezielle Pharmakologie and Toxikologie*, 7. Auflage. Spektrum Akademischer Verlag GmbH, Heidelberg-Berlin-Oxford.
- Franks, N. P., Dickinson, R., de Sousa, S. L., Hall, A. C. and Lieb, W. R. 1998. How does xenon produce anaesthesia? *Nature* 396:324.
- Freudig, B., Tesch, S. and Schubert, H. 2002. Herstellung von Emulsionen in Hochdruckhomogenisatoren - Teil 2: Bedeutung der Kavitation für die Tropfenzerkleinerung. *Chem Ing Tech* 74:880-884.
- Froeba, G. 1994. Personal Communication.
- Gäbler, R. and Schmidt, J. 1999. Xenon - Eine neue Alternative?(www.tu-dresden.de/medkai/989913.pdf, ed.) Klinik and Poliklinik für Anästhesiologie and Intensivtherapie, TU-Dresden.
- Georgieff, M., Froeba, G., Müller, H. R., Buttle, I. and Wachter, U. 2003. Intravenous xenon anaesthesia. In: 6th EuroSIVA Meeting on Intravenous Anaesthesia, Glasgow.
- Georgieff, M., Mückter, H., Fröba, G., Bäder, S., Liebl, B. and Marx, T. 1997. Xenon statt Lachgas? *Deutsches Ärzteblatt* 94:A2202-2205, B1792-1795, C1658-1661.
- Geyer, R. P., Watkin, D. M., Matthews, L. W. and Store, J. 1951. Parenteral nutrition. XI. Studies with stable and unstable fat emulsions administered intravenously. *Proc. Exp. Biology*. 77:872-876.
- Ghyczy, M. 1998. Arzneimittel mit Phosphatidylcholin and Liposomen: Entwicklung, Bewertung, Perspektiven In: *Pharmazeutische Technologie: Moderne Arzneiformen* (R. H. Müller and G. Hildebrand, Hrsg.). Wissenschaftliche Verlagsgesellschaft mbH Stuttgart.
- Gilead. 2003. Fachinformation. Gilead Sciences GmbH, Martiensried/München.
- Golaz, O., Hughes, G. J., Frutiger, S., Paquet, N., Bairoch, A., Pasquali, C., Sanchez, J.-C., Tissot, J.-D., Appel, R. D., Walzer, C., Balant, L. and Hochstrasser, D. F. 1993. Plasma and red blood cell protein maps: Update 1993. *Electrophoresis* 14:1223-1231.
- Goto, T., Nakata, Y. and Morita, S. 2003. Will xenon be a stranger or a friend?: the cost, benefit, and future of xenon anesthesia. *Anesthesiology* 98:1-2.
- Grau, M. J. 2000. Untersuchungen zur Lösungsgeschwindigkeit, Sättigungslöslichkeit and Stabilität von hochdispersen Arzneistoffsuspensionen. Dissertation. Pharmazeutische Technologie. Freie Universität.

- Gruda, I. and Dussault, N. 1988. Effect of the aggregation state of amphotericin B on its interaction with ergosterol. *Biochem Cell Biol* 66:177-183.
- Gummow, B., Swa, G. and Du Preez, J. 1994. A bioequivalence and pharmacokinetic evaluation of two commercial diminazene aceturate formulations administered intramuscularly to cattle. *Onderstepoort J Vet Res* 61:317-326.
- Hailer, S. and Wolfram, G. 1986. Influence on artificial fat emulsions on the composition of serum lipoproteins on the composition of serum lipoproteins in humans. *Am J Clin Nutr* 43:225-233.
- Hanash, S. M., Strahler, J. R., Sommerlot, L., Postel, W. and Görg, A. 1987. Two-dimensional electrophoresis with immobilized pH gradients in the first dimension: protein focusing as a function of time. *Electrophoresis* 8:229-234.
- Hann, I. M. and Prentice, H. G. 2001. Lipid-based amphotericin B: a review of the last 10 years of use. *Int J Antimicrob Agents* 17:161-9.
- Harnisch, S. 1998. Vergleichende Untersuchungen zur Plasmaproteinadsorption auf O/W-Emulsionen und Polymerpartikeln zur parenteralen Anwendung. Dissertation. Freie Universität Berlin.
- Heide, P. 2003. Amphotericin B in Fettemulsionen <http://medizin.freepage.de>.
- Heide, P. E. 1997. Precipitation of amphotericin B from i.v. fat emulsion. *Am J Health Syst Pharm* 54:1449.
- Heinemann, V., Kahny, B., Jehn, U., Muhlhaber, D., Debus, A., Wachholz, K., Bosse, D., Kolb, H. J. and Wilmanns, W. 1997. Serum pharmacology of amphotericin B applied in lipid emulsions. *Antimicrob Agents Chemother* 41:728-32.
- Heit, M. C. and Riviere, J. E. 1995. Antifungal and Antiviral Drugs. Pages 855-884. In: *Veterinary Pharmacology and Therapeutics* (H. R. Adams, ed.) Iowa State University Press, Ames (USA).
- Herbrecht, R. 1997. Safety of amphotericin B colloidal dispersion. *Eur J Clin Microbiol Infect Dis* 16:74-80.
- Hiemenz, J. W. and Walsh, T. J. 1996. Lipid formulations of amphotericin B: Recent progress and future directions. *Clin Infect Dis* 22:133-144.
- Hochstrasser, D. F., Harrington, M. E., Hochstrasser, A.-C. and Merrill, C. R. 1988. Methods for increasing the resolution of two-dimensional protein electrophoresis. *Anal Biochem* 173:424-435.
- Hunnus Pharmazeutisches Wörterbuch. 1992. 7. Auflage. Walter de Gruyter Berlin New York 1993.
- Jahnke, S. 1998. The theory of high-pressure homogenization. Pages 177-200. In: *Emulsions and Nanosuspensions for the formulation of poorly soluble drugs* (R. H. Müller, S. Benita and B. H. L. Böhm, Hrsg.). medpharm Scientific Publishers Stuttgart, Stuttgart.

- Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. and Crommelin, D. J. 1992. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet 23:279-91.
- Janoff, A. S., Perkins, W. R., Saeton, S. L. and Swenson, C. E. 1993. Amphotericin B lipid complex (ABLC) : a molecular rationale for the attenuation of amphotericin B-related toxicities. J Liposome Res 3:451-472.
- Jeppsson, R. and Rössner, S. 1975. The influence of emulsifying agents and of lipid soluble drugs on the fractional removal rate of lipid emulsions from the blood stream of the rabbit. Acta Pharmacol Toxicol 37:134-144.
- Johansen, H. K. and Gotzsche, P. 2000. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 3:CD000969.
- Johnson, R. C., Young, S. K., Cotter, R., Lin, L. and Rowe, W. B. 1990a. Medium-chain-triglyceride lipid emulsion: metabolism and tissue distribution. Am J Clin Nutr 52:502-8.
- Johnson, R. C., Young, S. K., Cotter, R., Lin, L. and Rowe, W. B. 1990b. Medium-chain-triglyceride lipid emulsion: metabolism and tissue distribution. Am J Clin Nutr 52:502-508.
- Juliano, R. L., Grant, C. W. M., Barber, K. R. and Kalp, M. A. 1987. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 31:1-11.
- Karbstein, H. and Schubert, H. 1995. Einflußparameter auf die Auswahl einer Maschine zum Erzeugen feindisperser O/W-Emulsionen. Chem Ing Tech 67:616-619.
- Karlson, P. 1994. Kurzes Lehrbuch der Biochemie für Mediziner and Naturwissenschaftler, 14.Auflage. Georg Thieme Verlag Stuttgart.
- Kawilarang, C., R.T., Georghiou, K. and Groves, M. J. 1980. The effect of additives on the physical properties of a phospholipid-stabilized soybean oil emulsion. J Clin Hospit Pharm 5:151-160.
- Kennedy, R. R., Stokes, J. W. and Downing, P. 1992. Anesthesia and the inert gases with special reference to xenon. Anesth Intens Care 20.
- Kim, D. H., Iijima, H., Goto, K., Sakai, J., Ishii, H., Kim, H. J., Suzuki, H., Kondo, H., Saeki, S. and Yamamoto, T. 1996. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J Biol Chem 271:8373-80.
- Kirsh, R., Goldstein, R., Tarloff, J., Parris, D., Hook, J., Hanna, N., Bugelski, P. and Poste, G. 1988. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 158:1065-70.
- Klang, S. H., Parnas, M. and Benita, S. 1998. Emulsions as drug carriers - possibilities, limitations and future perspectives In: Emulsions and Nanosuspensions for the

- Formulation of Poorly Soluble Drugs (R. H. Müller, S. Benita and B. Böhm, Hrsg.). medpharm Scientific Publishers Stuttgart.
- Klose, J. 1975. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues - a novel approach to testing for induced point mutation in mammals. *Humangenetik* 26:211-234.
- Kolb, G., Wagner, G., Viardot, K. and Ulrich, J. 2001. Zur Herstellung von Feinemulsionen mittels Hochdruckdispergiereinheiten. *Chem Ing Tech* 73:84-87.
- Kreuter, J. 2001. Nanoparticulate systems for brain delivery of drugs. *Advanced Drug Delivery Reviews* 47:65-81.
- Kreuter, J. and Alyautdin, R. N. 2000. Using nanoparticles to target drugs to the central nervous system, the blood-brain barrier and drug delivery to the CNS.
- Kreuter, J., Alyautdin, R. N., Karkevich, D. A. and Sabel, B. A. 1997. Drug targeting to the nervous system by nanoparticles. United States Patent: 6,117,454.
- Kreuter, J., Alyautdin, R. N., Kharkevich, D. A. and Ivanov, A. A. 1995. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). *Brain Res* 674:171-174.
- Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C. and Alyautdin, R. 2002. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. *J Drug Target* 10:317-25.
- Lachmann, B., Armbruster, S., Schairer, W., Landstra, M., Trouwborst, A., Van Daal, G. J., Kusuma, A. and Erdmann, W. 1990. Safety and efficacy of xenon in routine use as an inhalational anaesthetic. *Lancet* 335:1413-5.
- Lane, G. A., Nahrworld, M. L., Tait, A. R., Taylor-Busch, M. and Cohen, P. J. 1980. Anesthetics as teratogenes: nitrous oxide is fetotoxic, xenon is not. *Science* 210:899-901.
- Lang, S. 1990. Nebenwirkungsarme Lösungsvermittler für parenterale Arzneiformen (Paperback APV: Bd. 23). In: *Flüssige Arzneiformen schwerlöslicher Arzneistoffe* (D. Essig and H. Stumpf, Hrsg.). Wissenschaftliche Verlagsgesellschaft Stuttgart.
- Lawrence, J. H., Loomis, W. F., C.A., T. and Turpin, F. H. 1946. Preliminary observations on the narcotic effect of xenon with a review of values for solubilities of gases in water and oils. *J Physiol* 105:197-204.
- Lee, M. D., Hess, M. M., Boucher, B. A. and Apple, A. M. 1994. Stability of amphotericin B in 5% dextrose injection stored at 4°C or 25°C for 120 hours. *Am J Hosp Pharm* 51:394-396.
- Legrand, P., Vertut-Doi, A. and Bolard, J. 1996. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. *J Antimicrob Chemother* 37:519-533.
- Lewis, R. 2003. Antifungal therapy cost analysis(a. M. R. M. T. F. Patterson, ed.) www.doctorfungus.org.

- Lexikon der Biochemie und Molekularbiologie. 1995. Spektrum Akademischer Verlag GmbH, Heidelberg, Berlin, Oxford.
- Lich, A. 1991. Intravenös applizierfähige O/W-Emulsionen als Vehikel für schlecht lösliche mikronisierte Arzneistoffe. Marburg.
- Lipoid. 2002a. Produktdatenblatt Lipoid E 80. Lipoid GmbH, Ludwigshafen.
- Lipoid. 2002b. Produktdatenblatt Lipoid PC 14:0/14:0. Lipoid GmbH, Ludwigshafen.
- Lipoid. 2002c. Produktdatenblatt Lipoid S 75. Lipoid GmbH, Ludwigshafen.
- Lipoid. 2002d. Produktdatenblatt Lipoid S PC-3. Lipoid GmbH, Ludwigshafen.
- Lopez, R. M., Ayestaran, A., Pou, L., Montoro, J. B., Hernandez, M. and Caragol, I. 1996. Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion. *Am J Health Syst Pharm* 53:2724-2727.
- Lopez-Berestein, G., Mehta, R. T., Hopfer, R. L., Mills, K., Kasi, L., Mehta, K., Fainstain, V., Luna, M., Hersh, E. M. and Juliano, R. 1983. Treatment and prophylaxis of disseminated infection due to *Candida albicans* in mice with liposomal-encapsulated amphotericin B. *J Infect Dis* 147:939-945.
- Lück, M. 1997. Plasmaproteinadsorption als möglicher Schlüsselfaktor für eine kontrollierte Arzneistoffapplikation mit partikulären Trägern. Dissertation. Freie Universität Berlin.
- Lucks, J. S. 1993. Parenterale Fettemulsionen als Arzneistoffträger - Herstellung, Charakterisierung and Stabilität. Dissertation. Christian-Albrechts-Universität zu Kiel.
- Luttrupp, H. H., Thomasson, R., Dahm, S., Persson, J. and Werner, O. 1994. Clinical experience with minimal flow xenon anesthesia. *Acta Anaesthesiol Scand* 38:121-5.
- Lynch, C., 3rd, Baum, J. and Tenbrinck, R. 2000a. Xenon anesthesia. *Anesthesiology* 92:865-8.
- Lynch, C., Baum, J. and Tenbrinck, R. 2000b. Xenon anesthesia. *Anesthesiology* 92:865-868.
- Ma, D., Wilhelm, S., Maze, M. and Franks, N. P. 2002. Neuroprotective and neurotoxic properties of the 'inert' gas, xenon. *Br J Anaesth* 89:739-46.
- Maesaki, S. 2002. Drug Delivery System of Anti-fungal and Parasitic Agents. *Curr Pharm Des* 8:433-440.
- Magdassi, S. and Siman-Tov, A. 1990. Formation and stabilization of perfluorocarbon emulsions. *Int J Pharm* 59:69-72.
- Marzullo, L., Souza, L. C. and Campa, A. 1997. Effect of amphotericin B associated with a lipid emulsion on the oxidative burst of human polymorphonuclear leukocytes. *Gen Pharmacol* 28:203-7.
- Mathew, M., Das Gupta, V. and Bailey, R. E. 1995. Stability of omeprazole solutions at various pH values as determined by high-performance liquid chromatography. *Drug Dev Ind Pharm* 21:965-971.

- Matthews, B. and Rhodes, C. T. 1970. Use of the Derjaguin, Landau, Verwey, and Overbeek Theory to interpret pharmaceutical suspension stability. *J Pharm Sci* 59:521-525.
- Mehta, J. 1997. Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? *Leukemia Research* 21:183-188.
- Mehta, R. T., McQueen, T. J., Keyhani, A. and Lopez-Berestein, G. 1994. Phagozyte transport as a mechanism for enhanced therapeutic activity of liposomal amphotericin B. *Chemotherapy* 40:256-264.
- Merck. 1996. Merck Index. 12. Aufl. Merck&Co., Whitehouse Station.
- Merisko-Liversidge, E. 2002. Nanocrystals: Resolving Pharmaceutical Formulation Issues associated with poorly water-soluble Compounds. In: *Particles*. Marcel Dekker, Orlando:49.
- Merisko-Liversidge, E., Sarpotdar, P., Bruno, J., Hajj, S., Wie, L., Peltier, N., Rake, J., Shaw, J. M., Pugh, S., Polin, L., Jonres, J., Torbett, T., Cooper, E. and Liversidge, G. 1996. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. *Pharm Res* 13:272-278.
- Merril, C. R., Goldman, D. and Van Keuren, M. L. 1982. Simplified silver protein detection and image enhancement methods in polyacrylamide gels. *Electrophoresis* 3:17-23.
- Merril, C. R., Schwitzer, R. C. and Van Keuren, M. L. 1979. Trace polypeptides in cellular extracts and human body fluids detected by two-dimensional electrophoresis and highly sensitive silver stain. *Proc Nat Acad Sci USA* 76:4335-4339.
- Messer. 2000. Stoffdatenblatt Xenon. Messer Griesheim GmbH, Krefeld.
- Meyer, C. E., Fancher, J. A., Schurr, P. E. and Webster, H. D. 1957. Composition, preparation and testing of an intravenous fat emulsion. *Metabolism* 6:591-6.
- Mizushima, Y., Hamano, T. and Yokoyama, K. 1982. Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsions. *Ann Rheumatic Dis* 41:263-267.
- Möller, H. E., Chawla, M. S., Chen, X. J., Driehuys, B., Hedlund, L. W., Wheeler, C. T. and Johnson, G. A. 1999. Magnetic resonance angiography with hyperpolarized ^{129}Xe dissolved in a lipid emulsion. *Magn Reson Med* 41:1058-64.
- Moreau, P., Milpied, N., Fayette, N., Rame, J. F. and Harousseau, J. L. 1992. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. *J Antimicrob Chemother* 30:535-541.
- Morgan, D. J., Ching, M. S., Raymond, K., Bury, R. W., Mashford, L., Kong, B., Sabto, J., Gurr, W. and Somogyi, A. A. 1983. Elimination of amphotericin B in impaired renal function. *Clin Pharmacol Ther* 34:248-253.
- Moribe, K., Maruyama, K. and Iwatsuru, M. 1999. Molecular localization and state of amphotericin B in PEG liposomes. *Int J Pharm* 193:97-106.

- Möschwitzer, J., Achleitner, G., Pomper, H. and Müller, R. H. 2004. Development of an intravenously injectable chemically stable aqueous omeprazol formulation by nanosuspension technology. *Eur J Pharm Biopharm* 58:615-619.
- Mosharraf, M. N., C. 1995. The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. *Int J Pharm* 122:35-47.
- Mueller, J. F. and Iacono, J. 1967. The Effects of Multiple Daily Infusions of a 15% Cottonseed Oil Emulsion in Humans. Pages 7-10. In: *Fette in der Medizin* (N. Henning and G. Berg, Hrsg.). Pallas Verlag, München.
- Müller, R. H. 1983. Polydispersität und elektrophoretische Beweglichkeit hochdispenser Systeme. Dissertation. Christian-Albrechts-Universität zu Kiel.
- Müller, R. H. 1996a. Zetapotential and Partikelladung in der Laborpraxis. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
- Müller, R. H. 1998. Nanosuspensionen - eine neue Formulierung für schwerlösliche Arzneistoffe In: *Pharmazeutische Technologie: Moderne Arzneiformen* (R. H. Müller and G. Hildebrand, Hrsg.). Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
- Müller, R. H. 2001. Dispersions for the formulation of slightly or poorly soluble drugs. PCT/EP01/08726.
- Müller, R. H., Becker, R., Kruss, B., Peters, K. 1999. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. United States Patent No. 5, 858, 410.
- Müller, R. H., Benita, S. and Böhm, B. 1998. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. *medpharm Scientific Publishers* Stuttgart.
- Müller, R. H. and Böhm, B. H. L. 1998. Nanosuspensions. Pages 149-174. In: *Emulsions and Nanosuspensions for the formulation of poorly soluble drugs* (R. H. Müller, S. Benita and B. H. L. Böhm, Hrsg.). *medpharm Scientific Publishers*, Stuttgart.
- Müller, R. H. and Böhm, B. H. L. 2001. Dispersion Techniques for Laboratory and Industrial Scale Processing. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart.
- Müller, R. H. and Heinemann, S. 1992. Fat emulsions for parenteral nutrition. I: Evaluation of microscopic and laser light scattering methods for the determination of the physical stability. *Clin Nutr* 11:223-236.
- Müller, R. H. and Heinemann, S. 1993. Fat emulsions for parenteral nutrition. II: Characterisation and physical long-term stability of Lipofundin MCT/LCT. *Clin Nutr* 12:298-309.
- Müller, R. H., Lück, M. and Kreuter, J. 1997. Arzneistoffträgerpartikel für die gewebsspezifische Arzneistoffapplikation. DE 19745950A1.
- Müller, R. H., Lucks, J. S., Diederichs, J. E. and Heinemann, S. 1992. Lecithin Stabilized Emulsions for Parenteral Nutrition, a Three-Year Stability Study. In: *6th Int. Conf. On Technol. (APGI)*:351-360.

- Müller, R. H., Mäder, K., Krause K. 2000. Verfahren zur schonenden Herstellung von hochfeinen Micro-/Nanopartikeln. PCT Application PCT/EP00/06535.
- Muller, R. H., Schmidt, S., Buttle, I., Akkar, A., Schmitt, J. and Bromer, S. 2004. SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs. *Int J Pharm* 269:293-302.
- Müller, R. H., Schuhmann, R. 1996b. Teilchengrößenmessung in der Laborpraxis. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
- Musser, J. B., Fontana, J. L. and Mongan, P. D. 1999. The anesthetic and physiologic effects of an intravenous administration of a halothane lipid emulsion (5% vol/vol). *Anesth Analg* 88:671-5.
- Mutschler, E., Geisslinger, G., Kroemer, H. K. and Schäfer-Korting, M. 2001. Arzneimittelwirkungen, Lehrbuch der Pharmakologie and Toxikologie. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- Mykosen Online Redaktion. 2002a. Amphotericin B colloidal dispersion (ABCD/Amphocil®). www.mykosen-online.de.
- Mykosen Online Redaktion. 2002b. Wirkungsmechanismus. www.mykosen-online.de.
- Nakata, Y., Goto, K., Saito, H., Ishiguro, Y., Terui, K., Kawakami, H., Tsuruta, Y., Niimi, Y. and Morita, S. 2000. Plasma concentration of fentanyl with xenon to block somatic and hemodynamic responses to surgical incision. *Anesthesiology* 92:1043-1048.
- Nakata, Y., Goto, T. and Morita, S. 1997. Comparison of inhalation with xenon and sevoflurane. *Acta Anaesthesiol Scand* 41.
- Nalos, M., Wachter, U., Pittner, A., Georgieff, M., Radermacher, P. and Froeba, G. 2001. Arterial and mixed venous xenon blood concentrations in pigs during wash-in of inhalational anaesthesia. *Br J Anaesth* 87:497-8.
- Nasner, A. and Kraus, L. 1982. Neues aus der Lecithinforschung. *Deutsche Apothekerzeitung* 122:2407-2415.
- Nath, C. E., Shaw, P. J., Gunning, R., McLachlan, A. J. and Earl, J. W. 1999. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. *Antimicrob Agents Chemother* 43:1417-23.
- Nucci, M., Loureiro, M., Silveira, F., Casali, A. R., Bouzas, L. F., Velasco, E., Spector, N. and Pulcheri, W. 1999. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. *Antimicrob Agents Chemother* 43:1445-8.
- Oakley, B. R., Kirsh, D. R. and Morris, N. R. 1980. A simplified ultrasensitive silver stain for detecting proteins in polyacrylamide gels. *Anal Biochem* 105:361-363.
- O'Farrel, P. H. 1975. High resolution two-dimensional electrophoresis of proteins. *J Biol Chem* 250.

- Owens, D., Fleming, R. A., Restino, M. S., Cruz, J. M. and Hurd, D. D. 1997. Stability of amphotericin B 0.05 and 0.5 mg/ml in 20% fat emulsion. *Am J Health Syst Pharm* 54:683-686.
- Parnham, M. J. 1992. Liposome Phospholipids, Toxicological and Environmental Advantages. Pages 57-65. In: Griesbach Conference Liposome Dermatics (O. Braun-Falco and H. C. Korting, Hrsg.). Springer Verlag Berlin, Heidelberg, New York.
- Parnham, M. J. 1998. Safety and tolerability of intravenously administered phospholipid emulsions In: Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs (R. H. Müller, S. Benita and B. Böhm, Hrsg.). medpharm Scientific Publishers Stuttgart.
- Parnham, M. J. and Wendel, A. 1992. Phospholipids and liposomes - safety for cosmeceutical and pharmaceutical use. Nattermann Phospholipid GmbH, Scientific Publication Nr. 2.
- Patterson, T. F. and McGinis, M. R. 2003. Amphotericin B Coloidal Dispersion (ABCD)(T. F. Patterson and M. R. McGinis, eds.). www.doctorfungus.org.
- Perez-Soler, R., Khokhar, A. R., Hacker, M. P. and Lopez-Berenstein, G. 1986. Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum (II) encapsulated in multilamellar vesicles. *Cancer Res* 46:6269-6273.
- Peters, K. 1999. Nanosuspensionen - ein neues Formulierungsprinzip für schwerlösliche Arzneistoffe. Freie Universität Berlin.
- Petzelt, C., Taschenberger, G., Schmehl, W. and Kox, W. J. 1999. Xenon-induced inhibition of Ca²⁺-regulated transition in the cell cycle of human endothelial cells. *Pflugers Arch* 437:737-744.
- Phillips, J. O., Metzler, M. H., Palmieri, M. T., Huckfeldt, R. E. and Dahl, N. G. 1996. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. *Crit Care Med* 24:1793-1800.
- Plumb, D. 1999. Veterinary Drug Handbook. PharmaVet Publishing, White Bear Lake (USA).
- Poehling, H.-M. and Neuhoff, V. 1981. Visualization of proteins with a silver "stain": A critical analysis. *Electrophoresis* 2:141-147.
- Powell, M. F., Nguyen, T. and Baloian, L. 1998. Compendium of excipients for parenteral formulations. *PDA J Pharm Sci Technol* 52:238-311.
- Pyle, R. L. 1981. Clinical pharmacology of amphotericin B. *J Am Vet Med Assoc* 179:83-4.
- Quercia, R. A., Fan, C., Liu, X. and Chow, M. S. 1997. Stability of omeprazole in an extemporaneously prepared oral liquid. *Am J Health Syst Pharm* 54:1833-6.
- Ranchere, J. Y., Latour, C., Fuhrmann, C., Lagallarde, C. and Loreuil, F. 1996. Amphotericin B in intralipid formulations: stability and particle size. *J Antimicrob Chemother* 37:1165-1169.

- Rawle, A. 1995. PCS in 30 minutes, Malvern Instruments. In: Arbeitsunterlagen zu "Colloidal Drug Carriers - 1st Expert Meeting". Malvern Instruments, Berlin.
- Rehmert, G. C., Kwok, W. M., Weigt, H. U., Georgieff, M. and Bosnkak, Z. J. 1998. Xenon does not inhibit cardiac ion channels. *Anesthesiol Intensivmed Notfallmed Schmerzther* S33:E402.2.
- Reyle-Hahn, M. and Rossaint, R. 2000. Xenon-ein neues Anästhetikum. *Anaesthesist* 49:869-74.
- Robinson, R. F. and Nahata, M. C. 1999. A comparative review of conventional and lipid formulations of amphotericin B. *J Clin Pharm Ther* 24:249-57.
- Rossaint, R., Reyle-Hahn, M., Schulte Am Esch, J., Scholz, J., Scherpereel, P., Vallet, B., Giunta, F., Del Turco, M., Erdmann, W., Tenbrinck, R., Hammerle, A. F. and Nagele, P. 2003. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. *Anesthesiology* 98:6-13.
- RoteListe[®]. 2003. Editio Cantor Verlag, Aulendorf.
- Rothon, D. R., Mathias, R. G. and Schechter, M. T. 1994. Prevalence of HIV infection in provincial prisons in British Columbia. *Can J Med Assoc* 151:154-160.
- Rydhag, L. 1979. The importance of the phase behaviour of phospholipids for emulsion stability. *Fette, Seifen, Anstrichmittel* 81:168-173.
- Sandkühler, J. 2000. Learning and memory in pain pathways. *Pain* 88:113-118.
- Sandkühler, J., Benrath, J., Brechtel, C., Ruscheweyh, R. and Heinke, B. 2000. Chapter 6: Synaptic mechanisms of hyperalgesia. Pages 81-100. In: *Progress in Brain Research* (J. Sandkühler, B. Bromm and G. F. Gebhart Hrsg.). Elsevier Science B.V.
- Schenk, H.-D., Korff, G., Blei, A., Weingarten, J., Schäfer, G. and Schauder, P. 1990. Prospektive, randomisierte Studie zur Bedeutung von LCT, LCT/MCT (50:50) sowie MCT/LCT (70:30) für die parenterale Ernährung.I. Einfluß auf Blutfette, Leberenzyme and Leukozyten. *Infusionsther* 17:48.
- Schmidt, S. 2002. Parenterale O/W-Emulsionen: Plasmaproteininteraktionen and Inkorporation von Arzneistoffen. Dissertation. Freie Universität Berlin.
- Schmitt, W. 2000. Parenterale Ernährung - vom reinen Nährstoff zum metabolic support beim Intensivpatienten. *ellipse* 16:107-112.
- Schöffski, P., Freund, M., Wunder, R., Petersen, D., Kohne, C. H., Hecker, H., Schubert, U. and Ganser, A. 1998. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. *Bmj*. 317:379-84.
- Schreier, S., Malheiros, S. V. and de Paula, E. 2000. Surface active drugs: self-association and interaction with membranes and surfactants. *Physicochemical and biological aspects*. *Biochim Biophys Acta* 1508:210-34.

- Schricker, T. 1993. Bedeutung der Fette als Energieträger, Membranbausteine and Immunmodulatoren in der parenteralen Ernährung. *Anästhesiol Intensivmed Notfallmed Schmerzther* 28:240-243.
- Schroeder, H. G., Bivins, B. A., Sherman, G. P. and DeLuca, P. P. 1978. Physiological effects of subvisible microspheres administered intravenously to beagle dogs. *J Pharm Sci* 67:508-13.
- Schubert, H. and Armbruster, H. 1989. Prinzip der Herstellung und Stabilität von Emulsionen. *Chem Ing Tech* 61:701-711.
- Schubert, O. and Wretling, A. 1961. I.v. Infusion of Fat Emulsions, Phosphatides and Emulsifying Agents. *Acta Chir. Scand. (Suppl)* 278:1-21.
- Schuhmann, R. 1995. Physikalische Stabilität parenteraler Fettemulsionen - Entwicklung eines Untersuchungsschemas unter besonderem Aspekt analytischer Möglichkeiten. Freie Universität Berlin.
- Schuhmann, R. 1998. Präparate zur parenteralen Ernährung In: *Pharmazeutische Technologie: Moderne Arzneiformen* (R. H. Müller and G. Hildebrand, Hrsg.). Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
- Schuhmann, R. and Müller, R. H. 1994. Physical long term stability of Lipofundin fat emulsions for parenteral nutrition. *Eur J Pharm Sci* 2:186.
- Schultz, S., Wagner, G. and Ulrich, J. 2002. Hochdruckhomogenisation als ein Verfahren zur Emulsionsherstellung. *Chem Ing Tech* 74:901-909.
- Shadkchan, Y. and Segal, E. 2001. Treatment of experimental candidosis with amphotericin B-Intralipid admixtures in immunocompromised mice. *J Antimicrob Chemother* 48:245-251.
- Shadkchan, Y., Zaslavsky, Z. and Segal, E. 2003. Pharmacokinetics of amphotericin B in serum and tissues in mice treated with amphotericin B-Intralipid. *Med Mycol* 41:15-19.
- Shadkhan, Y., Segal, E., Bor, A., Gov, Y., Rubin, M. and Lichtenberg, D. 1997. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. *J Antimicrob Chemother* 39:655-8.
- Sievers, T. M., Kubak, B. M. and Wong-Beringer, A. 1996. Safety and efficacy of Intralipid emulsions of amphotericin B. *J Antimicrob Chemother* 38:333-47.
- Sigma-Aldrich. 2000. Sicherheitsdatenblatt Sigma-Aldrich Chemie GmbH, Steinheim.
- Simonelli, A. P., Mehta, S. C., Higuchi, W. I. 1970. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. *J Pharm Sci* 59:633-8.
- Singer, S. J. and Kramer, W. H. 1989. The fluid mosaic model of the structure of cell membranes. *Science* 175:720-731.
- Singh, M. and Ravin, L. J. 1986. Parenteral emulsions as drug carrier systems. *J. Parenter. Sci. Technol.* 40:34-41.

- Singla, A. K., Garg, A. and Aggarwal, D. 2002. Paclitaxel and its formulations. *International Journal of Pharmaceutics*. 235:179-92.
- Slack, J. D., Kanke, M., Simmons, G. H. and DeLuca, P. P. 1981. Acute hemodynamic effects and blood pool kinetics of polystyrene microspheres following intravenous administration. *J Pharm Sci* 70:660-4.
- Slain, D. 1999. Lipid-based amphotericin B for the treatment of fungal infections. *Pharmacotherapy* 19:306-323.
- Sommermeier, K. 1993. Pharmazeutische Entwicklung von Lipovenös 10% PLR. Pages 3-9. In: *Erfahrung mit einer modifizierten 10%igen Fettemulsion (Klinische Ernährung 37)* (Y. A. Carpentier, H.-J. Günther and E. Schlotzer, Hrsg.). W. Zuckerschwerdt Verlag München.
- Speiser, P. P. 1998. Poorly soluble drugs, a challenge in drug delivery In: *Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs* (R. H. Müller, S. Benita and B. Böhm, Hrsg.). medpharm Scientific Publishers Stuttgart.
- Spencer, C. M. and Faulds, D. 1994. Paclitaxel - A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. *Drugs* 48:794-847.
- SRC PhysProp Database Demo. <http://esc.syrres.com>.
- Stricker, H. 1987. *Physikalische Pharmazie* 3. Auflage. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart.
- Templin, S. 2003. Trypanosomosis: Neue Wirkstoffe für die Therapie and Carrier für das Gehirntargeting. Dissertation. Freie Universität Berlin.
- The Liposome Company. 2000. Produktmonographie Abelcet. The Liposome Company, Inc., Princeton, NJ, USA.
- Trissel, L. A. 1995. Amphotericin B does not mix with fat emulsion. *Am J Health Syst Pharm* 52:1463-1464.
- Troester, F. and Müller, R. H. 2004. Cremophor-free aqueous paclitaxel nanosuspension-production and chemical stability. In: *Annual Meeting of the Controlled Release Society (CRS)*, Honolulu.
- Walker, S., Taylor, S. A., Lee, M., Louie, L., Louie, M. and Simor, A. E. 1998. Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity. *Antimicrob Agents Chemother* 42:762-6.
- Wallhäußer, K. H. 1988. *Praxis der Sterilisation Desinfektion-Konservierung*. Georg Thieme Verlag, Stuttgart.
- Wallmark, B. 1986. Mechanism of action of omeprazole. *Scand J Gastroenterol Suppl* 118:11-17.
- Walsh, T. J., Yeldandi, V., McEvoy, M., Gonzalez, C., Chanock, S., Freifeld, A., Seibel, N. I., Whitcomb, P. O., Jarosinski, P., Boswell, G., Bekersky, I., Alak, A., Buell, D., Barret,

- J. and Wilson, W. 1998. Safety, tolerance, and pharmacokinetics of small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. *Antimicrob Agents Chemother* 42:2391-2398.
- Wasan, K. M. and Lopez, R. M. 1996. Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. *Clin Infect Dis* 23:1126-1138.
- Wasan, K. M. and Lopez, R. M. 1997. Diversity of lipid-based polyene formulations and their behavior in biological systems. *Eur J Clin Microbiol Infect Dis* 16:81-82.
- Washington, C. 1992. Particle size analysis in pharmaceuticals and other industries. Ellis Horwood, London.
- Washington, C. and Davis, S. S. 1987. Ageing effects in parenteral fat emulsions: the role of fatty acids. *Int J Pharm* 39:33-37.
- Washington, C., Lance, M. and Davis, S. S. 1993. Toxicity of amphotericin B emulsion formulations. *J Antimicrob Chemother* 31:806-8.
- Washington, C., Taylor, S. J. and Davis, S. S. 1988. The structure of colloidal formulations of amphotericin B. *J Infect Dis* 123:341-350.
- Weigt, H. U., Georgieff, M., Beyer, C., Georgieff, E. M., Kuhse, J. and Föhr, K. J. 2004. Lipid emulsions reduce NMDA-evoked currents. *Neuropharm* 47:373-380.
- Weigt, H. U., Georgieff, M., Beyer, C., Wachter, U. and Föhr, K. J. 2003. Xenon incorporated in a lipid emulsion inhibits NMDA receptor channels. *Acta Anaesthesiol Scand* 47:1119-24.
- Weigt, H. U., Georgieff, M., Georgieff, E. M. and Föhr, K. J. 2001. Xenon incorporated in a lipid emulsion inhibits neuronal NMDA Receptors. In: *ASA Annual Meeting, New Orleans*. 95:A708.
- Weigt, H. U., Kwok, W. M., Rehmert, G. C. and Bosnkak, Z. J. 1998. Modulation of the cardiac sodium current by inhalational anesthetics in the absence and presence of beta-stimulation.
- Weiner, B. B. 1984. Particle and droplet sizing using Fraunhofer diffraction. Pages 135-172. In: *Modern methods of particle size analysis* (H. G. Barth, ed.) J. Wiley & Sons, New York.
- Westermeier, R. 1990. *Elektrophorese Praktikum*. VCH Verlagsgesellschaft, Weinheim.
- Windholz, M., Budavari, S., Blumetti, R. and Otterbein, E. 1983. Amphotericin B. Pages 2194. In: *The Merck Index*.
- Wong-Beringer, A., Jacobs, R. A. and Guglielmo, B. J. 1998. Lipid formulations of amphotericin B: clinical efficacy and toxicities. *Clin Infect Dis* 27:603-18.
- Wretling, A. 1981. A development of fat emulsions. *J Parenter Enteral Nutr* 5:230-235.

- Yonas, H., Grungy, B. and Cook, E. 1981. Side effects of xenon inhalation. *J Comput Assist Tomogr* 5.
- Zheng, J., Harris, C. C. and Somasundaran, P. 1997. The effect of additives on stirred media milling of limestone. *Powder Technology* 91:173-179.
- Zimmermann, I. 1995. Possibilities and limitations of laser light scattering techniques for particle size analysis. In: *Arbeitsunterlagen zu "Colloidal Drug Carriers - 1st Expert Meeting, Berlin*.